期刊
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
卷 7, 期 -, 页码 57-71出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/COPD.S27320
关键词
COPD; FEV1; spirometry; exacerbation; inhaled corticosteroid; bronchodilator
资金
- Merck Sharp Dohme Corp
- AstraZeneca via University of Kentucky
- Boehringer Ingelheim-Pfizer via University of Kentucky
- Merck via University of Kentucky
- Novartis via University of Kentucky
- Almirall
- AstraZeneca
- Boehringer-Ingelheim
- Dey Laboratories
- Merck
- Novartis
- Pfizer
- Sepracor
- Forest Laboratories
- GlaxoSmithKline
- MAP Pharma (AstraZeneca)
- Sepracor (Sunovion)
- Teva
Rationale: The purpose of this study was to investigate the clinical efficacy and safety of a fixed-dose combination of mometasone furoate/formoterol fumarate (MF/F) administered via a metered-dose inhaler in subjects with moderate-to-very severe chronic obstructive pulmonary disease (COPD). Methods: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment period and a 26-week safety extension. Subjects (n = 1196), at least 40 years old, were current or ex-smokers randomized to twice-daily inhaled MF/F 400/10 mu g, MF/F 200/10 mu g, MF 400 mu g, F 10 mu g, or placebo. The trial's co-primary endpoints were mean changes from baseline, as area under the curve (AUC), in forced expiratory volume (FEV1) over 0-12 hours (AUC(0-12 h) FEV1) with MF/F versus MF, and in morning (AM) pre-dose (trough) FEV1 with MF/F versus F after 13 weeks of treatment. Key secondary endpoints were the effects of MF/F on respiratory health status using the Saint George's Respiratory Questionnaire (SGRQ), symptom-free nights, partly stable COPD at 26 weeks, and time to first COPD exacerbation. Results: The largest improvements in AUC(0-12 h) FEV1 were observed with MF/F 400/10 mu g and MF/F 200/10 mu g. Serial spirometry results demonstrated that bronchodilator effects with MF/F occurred rapidly (within 5 minutes), persisted for 12 hours after dosing, and were sustained over the 26-week treatment period. Similar findings were observed for AM pre-dose FEV1, for which effects were further investigated, excluding subjects whose AM FEV1 data were incorrectly collected after 2 days from the last dose of study treatment. Improvements in SGRQ scores surpassed the minimum clinically important difference of more than four units with both MF/F treatments. At 26 weeks, no notable between-treatment differences in the occurrence and nature of adverse events (AEs) were reported. No unexpected AEs were observed. Overall, 90 subjects reported AEs considered to be treatment-related, the most common of which were lenticular opacities, dysphonia, and oral candidiasis. Discussion: In conclusion, MF/F treatments improved lung function and respiratory health status, reduced exacerbations, and were well tolerated in subjects with moderate-to-very severe COPD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据